Opthea (NASDAQ:OPT) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Opthea (NASDAQ:OPT) has received a "sell (D-)" rating from Weiss Ratings, indicating a negative outlook on its stock performance.
• The company's stock traded at $3.41, with a 12-month range of $1.79 to $6.30.
• Institutional investors have increased their stakes in Opthea significantly, with Regal Partners Ltd raising its position by 78.6% in the first quarter.

Opthea (NASDAQ:OPT - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by stock analysts at Weiss Ratings in a note issued to investors on Tuesday,Weiss Ratings reports.

Opthea Price Performance

Opthea stock traded up $0.23 during trading hours on Tuesday, hitting $3.41. 3,000 shares of the stock were exchanged. Opthea has a 12 month low of $1.79 and a 12 month high of $6.30. The business's 50-day moving average is $3.41 and its two-hundred day moving average is $3.41.

Institutional Trading of Opthea

Institutional investors have recently bought and sold shares of the business. EP Wealth Advisors LLC acquired a new position in Opthea during the 1st quarter worth approximately $34,000. OLD Mission Capital LLC lifted its stake in shares of Opthea by 78.7% in the first quarter. OLD Mission Capital LLC now owns 19,167 shares of the company's stock valued at $65,000 after buying an additional 8,439 shares in the last quarter. Twin Lakes Capital Management LLC lifted its position in shares of Opthea by 67.4% during the first quarter. Twin Lakes Capital Management LLC now owns 33,156 shares of the company's stock valued at $113,000 after purchasing an additional 13,350 shares in the last quarter. Finally, Regal Partners Ltd raised its position in Opthea by 78.6% in the first quarter. Regal Partners Ltd now owns 5,193,688 shares of the company's stock worth $17,710,000 after acquiring an additional 2,286,285 shares during the period. Institutional investors own 55.95% of the company's stock.

Opthea Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.